I'm sorry, I didn't catch your name
generic ambien sublingual Long term, Lilly is betting that diabetes treatments--empagliflozin included--will buoy its results. It's sinking $1 billion into insulin production around the world to feed anticipated demand. Already, its Humalog and Humulin sales helped make third-quarter revenues a pleasant surprise. If the three diabetes meds it's hoping to get to market next year actually make it there, that could put Lilly on the right track. Of course, many drugmakers are making similar bets on diabetes, so the company will be scrapping for share.